Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is moving its lead oncology candidate, ONC010, closer to future clinical studies as it works to address treatment resistance in cancer. The company said it has achieved kilogram-scale manufacturing of a key precursor for ONC010’s active pharmaceutical ingredient, a step intended to support formulation development, GMP production, and preparation for clinical trials.

The manufacturing milestone forms part of Onco-Innovations’ broader effort to establish the infrastructure required for first-in-human studies. In drug development, scaling precursor production can be an important step before producing clinical-grade material under good manufacturing practice standards, because it helps support consistency, formulation work, and supply planning. ONC010 is being developed as a PNKP inhibitor, a drug candidate designed to interfere with DNA repair mechanisms in cancer cells. By targeting those mechanisms, the candidate is intended to address resistance to existing therapies.

Onco-Innovations has also reported several recent development and partnership activities tied to ONC010. The company signed a letter of intent with Nanosoft Polymers to advance polymer development and optimize drug delivery. It has also engaged Nucro-Technics for bioanalytical development and Avance Clinical for clinical and regulatory planning. The company said these relationships support ONC010’s formulation work and its regulatory pathway.

The development comes as drugmakers continue to seek new approaches for tumors that are resistant to current treatments. PNKP inhibitors are designed to exploit vulnerabilities in cancer cell DNA repair pathways, an approach that could potentially improve the effectiveness of chemotherapy and radiation. Onco-Innovations’ progress in manufacturing and external development partnerships is aimed at helping ONC010 move through the transition from preclinical work toward clinical evaluation, where safety, dosing, and early biological activity are typically assessed before later-stage efficacy studies.

Onco-Innovations is a Canadian-based company focused on cancer research. The company holds an exclusive worldwide license to patented technology targeting solid tumors and says its mission is centered on research and innovative solutions for cancer prevention and treatment. The company’s website is

News and updates relating to ONNVF are available through the company’s newsroom at As Onco-Innovations continues development of ONC010, future clinical data would be needed to assess the PNKP inhibition approach and its potential role for patients with treatment-resistant cancers.